Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Point Therapeutics has presented encouraging preclinical data for talabostat, including data showing that the targeted agent inhibits two new enzymes key to regulating tumor growth and immune responses.
Subscribe to our email newsletter
Talabostat inhibits dipeptidyl peptidases (DPPs), which are enzymes that regulate biological processes, including tumor growth and immune responses. As a stromal targeted agent, talabostat inhibits fibroblast activation protein (FAP), a DPP that has been shown to contribute to tumor growth.
Point Therapeutics has now revealed that talabostat also targets DPP 8 and DPP 9, which have been demonstrated to enhance immune functions in preclinical studies.
New preclinical data presented at the company's recent R&D day show that talabostat's inhibition of DPP 8 and DPP 9 may enhance immune functions and promote the body's natural ability to fight cancer.
“These proof of concept data are important because they validate a preclinical mechanism that is quite unique in oncology. The very nature of talabostat's dual mechanism of action speaks to its potential versatility as a targeted agent with broad utility in several different cancers,” said Dr Charles Dinarello, a professor of medicine at the University of Colorado School of Medicine.